Get the Stockscreener App
2.205
14.07%
0.215
Acrivon Therapeutics Inc stock is traded at $2.205, with a volume of 8.81M.
It is up +14.07% in the last 24 hours and up +18.84% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$1.99
Open:
$2.26
24h Volume:
8.81M
Relative Volume:
6.67
Market Cap:
$69.52M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.7932
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+8.61%
1M Performance:
+18.84%
6M Performance:
+60.99%
1Y Performance:
-71.66%
1-Day Range:
$2.17
$2.38
1-Week Range:
$1.88
$2.38
52-Week Range:
$1.05
$8.74
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
2.21 | 62.60M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.98 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.24 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.40 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
824.45 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
181.60 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-05-25 | Resumed | Piper Sandler | Overweight |
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech
Is Acrivon Therapeutics Inc. stock attractive for hedge fundsInsider Selling & Real-Time Price Movement Reports - newser.com
Is Acrivon Therapeutics Inc. stock supported by strong cash flows2025 Momentum Check & Weekly Sector Rotation Insights - newser.com
Will Acrivon Therapeutics Inc. stock split attract more investors2025 Trading Recap & Consistent Growth Stock Picks - newser.com
What high frequency data says about Acrivon Therapeutics Inc.Weekly Trend Recap & AI Driven Price Predictions - newser.com
Custom strategy builders for tracking Acrivon Therapeutics Inc.July 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Can Acrivon Therapeutics Inc. stock weather global recessionMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Analysts Predict Up to 550% Rally for These 2 ‘Strong Buy’ Penny Stocks - Yahoo Finance
Why Acrivon Therapeutics Inc. stock is recommended by analystsJuly 2025 Closing Moves & Community Verified Trade Signals - newser.com
Will Acrivon Therapeutics Inc. rebound enough to break evenDip Buying & Free Reliable Trade Execution Plans - newser.com
Is Acrivon Therapeutics Inc. stock a contrarian buyWeekly Profit Analysis & Daily Chart Pattern Signal Reports - newser.com
Will Acrivon Therapeutics Inc. stock benefit from green energy trendsJuly 2025 Levels & Weekly High Momentum Picks - newser.com
Acrivon Therapeutics’ Phase 1 Study of ACR-2316: Key Updates and Market Implications - TipRanks
Acrivon Therapeutics Advances Phase 2 Study for Endometrial Cancer Treatment - TipRanks
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.68%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):